Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 7/20 | 1.00 |
| ▸ | DYRK2 | Q92630 | 3/20 | 1.00 |
| ▸ | RAF1 | P04049 | 2/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | AKT1 | P31749 | 2/20 | 1.00 |
| ▸ | AKT2 | P31751 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 2/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 2/20 | 1.00 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 1.00 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | PRDX1 | Q06830 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29786707 | 1.00 | IKBKB (1.00) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL1325644 | 1.00 | IKBKB (1.00) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL30593591 | 1.00 | IKBKB (1.00) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL29363457 | 1.00 | IKBKB (1.00) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL8119310 | 1.00 | IKBKB (1.00) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| Hydrochloric Acid SCHEMBL29359400 | 0.98 | IKBKB (0.96) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| Acetic Acid SCHEMBL3187366 | 0.91 | IKBKB (0.82) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| Acetic Acid SCHEMBL3187370 | 0.91 | IKBKB (0.82) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL17300373 | 0.81 | IKBKB (0.67) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL8128818 | 0.80 | IKBKB (0.67) | IKBKBDYRK2RAF1RPS6KB1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590147-B1 | Spirooxindole-pyrrolothiazole heterocyclic hybrids | KING SAUD UNIVERSITY (SA) | 2020-03-17 | — | — | US | claimed |
| US-9173839-B2 | Anionic lipids and lipid nano-structures and methods of producing and using same | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2015-11-03 | — | — | US | claimed |
| US-20130243688-A1 | ANIONIC LIPIDS AND LIPID NANO-STRUCTURES AND METHODS OF PRODUCING AND USING SAME | UNIV OKLAHOMA (US) | 2013-09-19 | — | — | US | claimed |
| US-8420118-B2 | Anionic lipids and lipid nano-structures and methods of producing and using same | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2013-04-16 | — | — | US | claimed |
| WO-2011031849-A2 | ANIONIC LIPIDS AND LIPID NANOSTRUCTURES AND METHODS OF PRODUCING AND USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2011-03-17 | — | — | WO | claimed |
| US-20110059157-A1 | ANIONIC LIPIDS AND LIPID NANO-STRUCTURES AND METHODS OF PRODUCING AND USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2011-03-10 | — | — | US | claimed |
| US-6664272-B2 | Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue | EMORY UNIVERSITY | 2003-12-16 | — | — | US | claimed |
| US-20220291237-A1 | Gene Expression Inflammatory Age and Its Uses | Edifice Health, Inc. (US) | 2022-09-15 | — | — | US | disclosed |
| EP-2827890-B1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | UNIV QUEENSLAND (AU) | 2019-08-28 | — | — | EP | disclosed |
| EP-2441452-B1 | PHARMACEUTICAL COMPOSITION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT, PROPHYLAXIS OR PREVENTION OF NEOPLASTIC DISEASES IN HUMANS AND ANIMALS | UNIV ANHANGUERA DE SAO PAULO UNIAN SP (BR) | 2018-12-26 | — | — | EP | disclosed |
| US-9359196-B2 | Antiproliferative compositions comprising curcumin analogs and methods of producing and using same | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2016-06-07 | — | — | US | disclosed |
| US-9173839-B2 | Anionic lipids and lipid nano-structures and methods of producing and using same | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20060229239-A9 | Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis | SHOJI MAMORU | 2006-10-12 | — | — | US | disclosed |
| EP-1572078-A4 | NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS | UNIV EMORY (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1572078-A2 | NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS | Emory University (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050069551-A1 | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis | EMORY UNIVERSITY | 2005-03-31 | — | — | US | disclosed |
| WO-2005025623-A2 | EF-24-FACTOR VII CONJUGATES | EMORY UNIVERSITY (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20040009914-A1 | Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis | US GOVERNMENT - SECRETARY OF THE ARMY | 2004-01-15 | — | — | US | disclosed |
| WO-2003075847-A2 | NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS | EMORY UNIVERSITY (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | HLA-DRB1, CD74, CHI3L1 | IKBKB 584/4885DYRK2 4085/4885RAF1 4404/4885 |
| US-20060229239-A9 | Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis | F13B, F13A1, HABP2 | IKBKB 462/4885DYRK2 4139/4885RAF1 2623/4885 |
| US-10590147-B1 | Spirooxindole-pyrrolothiazole heterocyclic hybrids | BRD9, BRWD1, BRD7 | IKBKB 2776/4885DYRK2 1383/4885RAF1 508/4885 |
| US-20040009914-A1 | Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis | F13B, F13A1, HABP2 | IKBKB 462/4885DYRK2 4139/4885RAF1 2623/4885 |
| US-20050069551-A1 | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis | VEGFA, AGER, HDGF | IKBKB 1354/4885DYRK2 3834/4885RAF1 2562/4885 |
| US-20130243688-A1 | ANIONIC LIPIDS AND LIPID NANO-STRUCTURES AND METHODS OF PRODUCING AND USING SAME | SGMS2, SGMS1, PHOSPHO1 | IKBKB 4749/4885DYRK2 3848/4885RAF1 2160/4885 |
| US-20110059157-A1 | ANIONIC LIPIDS AND LIPID NANO-STRUCTURES AND METHODS OF PRODUCING AND USING SAME | SGMS2, SGMS1, PHOSPHO1 | IKBKB 4749/4885DYRK2 3848/4885RAF1 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.